Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison
A Prospective Comparative Study of a Novel Gadolinium-Weighted MRI Sequence Versus Conventional T1-Weighted Imaging for the Detection of Brain Metastases
Region Stockholm
100 participants
Jan 28, 2026
OBSERVATIONAL
Conditions
Summary
This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection. The purpose is to determine whether this novel "gadolinium-weighted" imaging method can detect more or smaller tumors than standard MRI techniques. Participants will undergo a routine brain MRI with contrast, followed by an additional scan using the new method. The goal is to improve diagnostic accuracy without increasing the contrast dose or scan time.
Eligibility
Inclusion Criteria5
- Age 18 years or older
- Scheduled for clinical brain MRI with gadolinium contrast
- Known or suspected brain metastases
- Able to provide informed consent
- Able to lie still for the duration of the MRI examination
Exclusion Criteria5
- Contraindications to MRI
- Known allergy or contraindication to gadolinium-based contrast agents
- Renal impairment (eGFR \< 30 mL/min/1.73m²)
- Pregnant or breastfeeding
- Inability to comply with study procedures
Interventions
A post-contrast MRI sequence incorporating magnetization transfer (MT) preparation and flow-nulling with motion-sensitized driven equilibrium (MSDE). The sequence is optimized to suppress background tissue and vascular signal while enhancing the visibility of gadolinium-enhancing brain metastases. It is compared to conventional T1-weighted imaging in the same exam session.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07272616